Of note, the NH600001 treatment groups, versus the etomidate group, show a decreasing trend in the incidence of myoclonus (7.5%, 5.0%, 7.5% vs 17.5%).
← all excerpts
NH600001, an etomidate analogue, provides gastrointestinal endoscopy sedation/anesthesia and reduces adrenocortical depression: two randomized controlled trials.
1
—
—